of patients with glioma experience stress during their hospitalization and thereafter. [4] Stress can have a potential role in the development of psychiatric disorder and seems to be of relevance in our case. A mood episode independent of glioma seems to be a sound explanation in this case.
Patient's manic symptoms resolved completely with sodium valproate, which is a potent antiepileptic agent as well as a mood stabilizer. Other antiepileptic agents like-phenytoin, phenobarbitone, topiramate, levetiracetam, lacosamide, zonisamide, and benzodiazepines lack the mood stabilizing the property. Choosing valproate as a medication for seizure prophylaxis, will not only ensure a seizure-free recovery; its mood stabilizing property will also take care of manic symptoms as well as aggression. The clinician needs to be cautious enough in considering the psychiatric diagnosis as well as selection of appropriate medication for its treatment. A multidisciplinary collaborative approach might be more useful in this regards.
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Valproate-induced Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
Sir, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome is a rare and life-threatening hypersensitivity reaction to drugs with a mortality rate of 10%-20%. Here, we report a case of valproate-induced DRESS syndrome encountered in a case of recurrent depressive disorder.
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Our patient, a 39-year-old male, with a history of depression (treated with escitalopram), presented to the hospital with gradually progressive low mood, irritability, and sleep disturbance for 2 months. He was diagnosed with recurrent depressive disorder and was started on escitalopram, augmented with Sodium Valproate. On remission, he was discharged on maintenance medication. Soon after discharge, he was admitted again (after 3 days) with fever and rash. Examination revealed macular rash with scaling and erythema all over the body, sparing face, and lymphadenopathy (inguinal, cervical, and axillary, >1 cm each). Investigations revealed raised leukocyte count (39,000/mm 3 ), with lymphocytosis (58%) and eosinophilia (9%). Hypersensitivity reaction was suspected, and all his drugs were stopped. Peripheral blood smear (PBS) and fine-needle aspiration cytology of lymph nodes revealed activated lymphocytes. After consultation with Physician and Dermatologist, he was diagnosed with DRESS in view of rash, fever, lymphadenopathy, transaminitis (Alanine Aminotransferase -295 IU/L and Aspartate Aminotransferase -190 IU/L), eosinophilia, and activated lymphocytes in PBS. He was started on high-dose Prednisolone (40 mg/day) along with other supportive measures. He showed gradual improvement in rash. Later, tablet Lithium was added as a mood stabilizer and was tolerated well. The patient was discharged in remission on maintenance medication.
The patient benefitted because of early detection and a high index of suspicion. The syndrome of DRESS, also known as Drug-Induced Hypersensitivity Syndrome (DIHS), is differentiated by multivisceral involvement, late onset of symptoms after the start of offending drug, (3 weeks to 3 months) and their possible persistence or worsening despite the withdrawal of the offending drug. [1] Criteria for the diagnosis have been given by the Japanese study group of severe cutaneous adverse reactions to drugs (SCAR-J) and the European group, RegiSCAR. In this case, definitive features of DRESS were present (score of 6 on RegiSCAR and 7 as per SCAR-J). Antibody titre for HHV-6 could not be done. Aromatic anticonvulsants most frequently associated with DRESS/DIHS are phenytoin, phenobarbital, and carbamazepine. Nonaromatic anticonvulsant drugs (e.g., topiramate and valproic acid) are generally considered safe. [2] However, there are published case reports of valproate-induced hypersensitivity reactions where valproate was used as anticonvulsant. [3] Given that valproate is used extensively in psychiatry and that such a reaction can be fatal, recognition of valproate-induced DRESS assumes importance.
